Antisense oligonucleotide mediated therapy of spinal muscular atrophyTranslational Neuroscience
AbstractSpinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA results from deletions or mutations of survival motor neuron 1 (SMN1), an essential gene. SMN2, a nearly identical copy, can compensate for SMN1 loss if SMN2 exon 7 skipping is prevented. Among the many cis-elements involved in the splicing regulation of SMN exon 7, intronic splicing silencer N1 (ISS-N1) has emerged as the most effective target for an antisense oligonucleotide (ASO)-mediated splicing correction of SMN2 exon 7. Blocking of ISS-N1 by an ASO has been shown to fully restore SMN2 exon 7 inclusion in SMA patient cells as well as in vivo. Here we review how ISS-N1 targeting ASOs that use different chemistries respond differently in the various SMA mouse models. We also compare other ASO-based strategies for therapeutic splicing correction in SMA. Given that substantial progress on ASO-based strategies to promote SMN2 exon 7 inclusion in SMA has been made, and that similar approaches in a growing number of genetic diseases are possible, this report has wide implications.
Copyright OwnerVersita Sp. z o.o.
Citation InformationSenthilkumar Sivanesan, Matthew D. Howell, Christine J. DiDonato and Ravindra N. Singh. "Antisense oligonucleotide mediated therapy of spinal muscular atrophy" Translational Neuroscience Vol. 4 Iss. 1 (2013) p. 1 - 7
Available at: http://works.bepress.com/ravindra-singh/4/